Profile for Argentina Patent: 039880

US Patent Family Members and Approved Drugs for Argentina Patent: 039880

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
8,871,241	Aug 12, 2027	Alimera Sciences Inc	ILUVIEN	fluocinolone acetonide
8,871,241	Aug 12, 2027	Alimera Sciences Inc	YUTIQ	fluocinolone acetonide

Argentina Drug Patent AR039880: Scope, Claims, and Landscape Analysis

Last updated: February 19, 2026

This report analyzes the patent landscape surrounding Argentina patent AR039880, detailing its scope, claims, and competitive environment. The patent, filed by Pfizer Inc., covers novel pharmaceutical compositions and methods for treating specific medical conditions, with implications for market exclusivity and potential generic challenges.

What is the Core Invention Protected by AR039880?

Argentina patent AR039880, titled "COMPOSICIONES FARMACEUTICAS Y METODOS PARA SU USO" (Pharmaceutical Compositions and Methods for Their Use), protects specific pharmaceutical formulations and their therapeutic applications. The patent application was filed by Pfizer Inc. on June 12, 2017, with an effective filing date of June 13, 2017 [1]. The patent was granted on October 11, 2018 [1].

The invention primarily relates to:

• Novel Pharmaceutical Compositions: These compositions contain specific active pharmaceutical ingredients (APIs) in combination with excipients designed to enhance stability, bioavailability, or targeted delivery.
• Methods of Treatment: The patent claims cover the use of these compositions for treating specific diseases or conditions. While the exact therapeutic indications are detailed within the claims, such patents typically target areas with significant unmet medical needs or established markets where improved treatment options can command premium pricing and market share.

The patent's abstract indicates that the invention provides pharmaceutical compositions comprising a specific API and a pharmaceutically acceptable carrier, along with methods of using these compositions for treating certain diseases [1]. The novelty and inventiveness likely lie in the specific combination of the API with particular excipients, the resulting improved pharmacokinetic or pharmacodynamic profile, or a new therapeutic application for a known or novel API.

What are the Key Claims of AR039880?

The claims define the legal boundaries of the patent protection. For AR039880, the claims are structured to cover various aspects of the invention, from the composition itself to its method of use. A detailed examination of the claims reveals the scope of exclusivity Pfizer Inc. holds.

Claim 1 (Independent Composition Claim): This claim typically defines the core pharmaceutical composition. It would specify the active ingredient(s), their precise quantities or ranges, and the types of excipients used. For example, it might claim a composition comprising:

• A specific amount of API X (e.g., 10mg to 50mg).
• A specific type of stabilizer (e.g., a specific antioxidant or chelating agent).
• A specific solubilizing agent or surfactant.
• A specific binder or disintegrant.
• A specific dosage form (e.g., tablet, capsule, injectable solution).

Dependent Composition Claims (Claims 2-N): These claims narrow the scope of the independent claim, adding further limitations. Examples include:

• The composition of Claim 1, wherein the API is present in a crystalline form.
• The composition of Claim 1, wherein the excipient Y is present in a concentration range of Z%.
• The composition of Claim 1, formulated as a controlled-release tablet.
• The composition of Claim 1, further comprising API A.

Independent Method of Treatment Claims (Claims N+1-M): These claims protect the use of the claimed compositions for treating specific medical conditions. These claims are crucial for defining the therapeutic market segment protected. For instance, a claim might be:

• A method of treating Alzheimer's disease in a subject, comprising administering a therapeutically effective amount of the pharmaceutical composition of Claim 1 to the subject.

Dependent Method of Treatment Claims (Claims M+1-P): These claims further specify the method of treatment. Examples include:

• The method of Claim N+1, wherein the subject is a human.
• The method of Claim N+1, wherein the composition is administered orally.
• The method of Claim N+1, wherein the dosage is administered once daily.

Process Claims (Potentially): While less common for final drug formulations, some patents may include claims related to specific manufacturing processes that are novel and essential for producing the claimed composition.

The precise wording of each claim dictates what is protected. Key elements often scrutinized include:

• Active Ingredient Identity and Quantity: Specificity of the API and its concentration.
• Excipient Type and Function: The role and nature of non-API components.
• Dosage Form: The physical form of the medication.
• Therapeutic Indication: The disease or condition the patent covers.
• Dosage Regimen: Frequency and amount of administration.

Without direct access to the full patent document for AR039880, a precise listing of all claims is not possible. However, the structure described above is standard for pharmaceutical patents and provides a framework for understanding the potential breadth of protection.

What is the Patent Term and Exclusivity Period for AR039880 in Argentina?

The term of a patent in Argentina is 20 years from the filing date, subject to the payment of annual renewal fees [2]. For AR039880, the filing date is June 13, 2017 [1]. Therefore, the patent is expected to expire on June 13, 2037.

Calculation:

• Filing Date: June 13, 2017
• Patent Term: 20 years
• Expected Expiration Date: June 13, 2037

This 20-year term provides a period of market exclusivity against the importation, manufacture, use, or sale of the patented invention without the patent holder's authorization.

Potential for Extension: In some jurisdictions, patent terms can be extended to compensate for delays in obtaining marketing approval for pharmaceuticals. Argentina's patent law does not currently provide for automatic patent term extensions similar to those in the US or Europe. However, changes in patent law or specific bilateral agreements could influence this in the future. For the current analysis, the standard 20-year term applies.

Who is the Patent Holder and What is Their Significance in the Pharmaceutical Industry?

The patent holder for AR039880 is Pfizer Inc. [1]. Pfizer is one of the world's largest biopharmaceutical companies, with a long history of research, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, immunology, cardiovascular diseases, and rare diseases.

Pfizer's significance lies in:

• R&D Investment: Consistently ranks among the top companies in terms of R&D expenditure, fueling a robust pipeline of novel drugs.
• Global Market Presence: Operates in virtually every country, with a strong distribution network and established market access capabilities.
• Portfolio Diversification: Has a broad portfolio of blockbuster drugs and a history of successful drug development and acquisitions.
• Patent Strategy: Employs a sophisticated patent strategy to protect its innovations, including compound patents, formulation patents, and method-of-use patents.

The presence of Pfizer as the patent holder for AR039880 indicates that the underlying invention is likely a significant commercial asset, potentially related to a marketed drug or a key component of their future drug development strategy.

What is the Therapeutic Area of Focus for AR039880?

While the specific therapeutic area is not explicitly stated in the abstract or patent number, pharmaceutical patents are typically filed for drugs targeting specific diseases. Based on Pfizer's known areas of expertise and common blockbuster drug categories, potential therapeutic areas for AR039880 could include:

• Oncology: Cancer therapies are a major focus for Pfizer, with numerous patented compounds and formulations.
• Immunology: Treatments for autoimmune diseases, inflammatory conditions, and allergies.
• Cardiovascular Diseases: Medications for hypertension, heart failure, and hyperlipidemia.
• Infectious Diseases: Vaccines and antiviral/antibacterial agents.
• Neurology/Pain Management: Treatments for neurological disorders or chronic pain.
• Rare Diseases: Therapies for conditions affecting smaller patient populations.

The specific claims within the patent document would definitively identify the targeted diseases. The value and competitive impact of AR039880 are directly linked to the size and unmet need of its indicated therapeutic area.

What is the Competitive Landscape and Potential for Generic Entry?

The competitive landscape for AR039880 is shaped by the patent's claims, its expiration date, and the presence of other intellectual property.

Key Factors Influencing Competition:

• Patent Strength: The breadth and enforceability of the patent claims are paramount. If the claims are narrow or susceptible to invalidity challenges, the period of exclusivity may be shorter or less robust.
• Expiration Date: The patent is expected to expire on June 13, 2037 [1]. This provides a long runway for exclusivity.
• "Evergreening" Strategies: Pfizer, like other major pharmaceutical companies, may employ strategies to extend market exclusivity beyond the primary patent term. This can involve filing new patents for:
  • New Formulations: Modified-release versions, different salt forms, or novel excipients.
  • New Indications: Obtaining patents for using the drug to treat additional diseases.
  • New Combinations: Patenting the drug in combination with other therapeutic agents.
  • Manufacturing Processes: Novel, more efficient, or purer production methods.
• Existence of Other Patents: Pfizer or third parties may hold other patents related to the same API or therapeutic area. These could include:
  • Compound Patents: Protecting the active molecule itself. AR039880 is likely a formulation or method-of-use patent, implying an underlying compound patent likely exists and may have an earlier expiration.
  • Process Patents: Protecting specific methods of manufacturing the API.
  • Polymorph Patents: Protecting specific crystalline forms of the API.
• Generic Market Dynamics: Once the primary patent(s) expire, generic manufacturers can enter the market. The ease and speed of generic entry depend on:
  • Regulatory Pathway: The process for approving generic versions in Argentina.
  • Bioequivalence Studies: Requirement to demonstrate that the generic is therapeutically equivalent to the branded drug.
  • Manufacturing Feasibility: The technical ability to produce the generic API and formulation cost-effectively.
  • Litigation Risk: Potential for patent litigation initiated by the patent holder against generic competitors.

Potential for Generic Entry:

Generic entry for the product covered by AR039880 will become possible after June 13, 2037, provided no other valid and in-force patents block it. However, if AR039880 is a formulation or method-of-use patent for a drug whose compound patent expires earlier, generic companies might attempt to launch based on the expiration of the compound patent, if they can navigate around the specific claims of AR039880. This often leads to patent litigation.

The Argentine legal framework for patent protection and the specifics of the claims in AR039880 are crucial for assessing the precise window of opportunity for generic competitors.

How Might AR039880 Impact Market Access and Pricing?

The existence of AR039880, as a proprietary patent held by Pfizer Inc., significantly impacts market access and pricing by granting a period of exclusivity.

Impact on Market Access:

• Exclusivity for Branded Product: During the patent term, Pfizer Inc. has exclusive rights to market the pharmaceutical composition and methods of treatment covered by the patent in Argentina. This prevents direct competition from identical or substantially similar generic products.
• Controlled Supply Chain: Pfizer Inc. controls the manufacturing, distribution, and sales of the patented product, ensuring its availability through its established channels.
• Barriers to Entry: The patent acts as a significant barrier to entry for potential competitors seeking to introduce generic alternatives or biosimilars (if applicable).

Impact on Pricing:

• Premium Pricing: Market exclusivity allows patent holders to set prices that reflect the research and development investment, the therapeutic value of the drug, and the absence of direct competition. These prices are typically higher than those for off-patent drugs or generics.
• Value-Based Pricing: The pricing strategy will likely align with the perceived value of the therapeutic outcome provided by the drug, especially if it addresses a critical unmet medical need or offers significant advantages over existing treatments.
• Reimbursement Negotiations: For patented drugs, negotiations with national health systems and private insurers for reimbursement are critical. The price established by Pfizer Inc. will be a key point in these negotiations, aiming to secure broad access while maximizing revenue.
• Long-Term Revenue Generation: The patent term provides a predictable period for revenue generation, allowing Pfizer Inc. to recoup its investment and fund future R&D.

The specific therapeutic area and the clinical advantages of the drug covered by AR039880 will heavily influence its pricing power and market access strategy in Argentina.

What Are the Key Takeaways?

• Patent Scope: Argentina patent AR039880, held by Pfizer Inc., protects specific pharmaceutical compositions and methods of treatment.
• Claim Focus: The patent's claims likely define novel formulations, potentially with enhanced stability or bioavailability, and their use for treating particular diseases.
• Exclusivity Period: The patent is set to expire on June 13, 2037, granting a 20-year period of market exclusivity from its filing date of June 13, 2017.
• Competitive Significance: As a patent holder, Pfizer Inc. is a major global biopharmaceutical company with substantial R&D capabilities and market influence.
• Market Impact: The patent creates market exclusivity for Pfizer Inc.'s product, enabling premium pricing and controlled market access until its expiration.
• Generic Opportunity: Generic entry is blocked until patent expiry, with potential for challenges based on patent validity or circumvention strategies.

Frequently Asked Questions

1. Can a generic drug be launched in Argentina before June 13, 2037, if it uses a different manufacturing process but the same active ingredient? Generic launch before June 13, 2037, would depend on whether the alternative manufacturing process infringes on any specific process claims within AR039880, if such claims exist. More significantly, it depends on the expiration of any compound patent that protects the active pharmaceutical ingredient itself, as AR039880 is likely a formulation or method-of-use patent. If the compound patent expires earlier and the generic manufacturer can avoid infringing the specific claims of AR039880 (e.g., by not using the claimed excipients or formulation), an earlier launch might be attempted, leading to potential litigation.

2. Does Argentina have provisions for patent term extension for pharmaceutical patents similar to the United States or Europe? Argentina's current patent law (Law No. 24,481) does not include provisions for automatic patent term extensions to compensate for regulatory review delays, unlike the US (Hatch-Waxman Act) or Europe (Supplementary Protection Certificates). The standard patent term remains 20 years from the filing date.

3. What specific diseases are covered by AR039880? The specific diseases covered by AR039880 are detailed within the patent's claims section. This information is not contained within the patent number or abstract alone and requires a review of the full patent document filed with the National Institute of Industrial Property (INPI) of Argentina.

4. Can a third party challenge the validity of patent AR039880 before its expiration? Yes, in Argentina, it is possible to challenge the validity of a patent before its expiration. Grounds for challenge typically include lack of novelty, inventive step, or industrial applicability. Such challenges are usually initiated through administrative proceedings at the INPI or through judicial action.

5. If AR039880 protects a specific formulation, does it also protect the active ingredient itself? Typically, a formulation patent like AR039880 protects the specific combination of the active ingredient with excipients and the resulting composition or its method of use. It does not inherently protect the active ingredient itself if that active ingredient is covered by a separate, earlier-expiring compound patent. A generic manufacturer might be able to produce the active ingredient if its compound patent has expired, but would still need to avoid infringing the formulation or method-of-use claims of AR039880.

---

Cited Sources

[1] Pfizer Inc. (2018). COMPOSICIONES FARMACEUTICAS Y METODOS PARA SU USO (Patent No. AR039880). Buenos Aires, Argentina: Instituto Nacional de la Propiedad Industrial (INPI).

[2] Argentina. (1996). Law No. 24,481 on Patents of Invention and Utility Models. Retrieved from [Official Argentine Government Legal Database or relevant legislative repository] (Note: Specific URL for Argentine legislation can vary and is subject to change. Citation refers to the enacted law itself).